Grant ID

01T-441

Illness

Schizophrenia

Primary Drug/Intervention

Risperidone

Primary Dosage

up to 0.6 mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Klushnik

Sample Size

32

Duration of Study Period for Each Subject

24 weeks

Outcome Measurements

PANSS, CGI

Results

N/A

Publication

N/A

Link

N/A

PI Name

Tatyana Klushnik

Degree

MD

Center

N/A

Institution

Mental Health Research Institute, RAMS

Address

City or Town

N/A

State or Province

N/A

Zip or Postal Code

N/A

Country

N/A

Email Address

klushnik@hotmail.com